The Study of Ciprofol for the Suppression of Cardiovascular Responses to Tracheal Intubation

Summary

Preliminary studies have illuminated the promising nature of ciprofol, indicating its enhanced safety spectrum, superior potency, and a diminished likelihood of experiencing injection-related discomfort. Venturing deeper, this research embarked on an ambitious quest to measure the 95% effective volume of ciprofol for induction of general anesthesia by a modified sequential method and juxtapose the 95% effective volume dosage of ciprofol against a corresponding dose of remimazolam during the initiation of general anesthesia. The study delved into diverse anesthetic protocols, meticulously scrutinizing the safety and efficacy credentials of ciprofol. The ultimate vision was to pave a robust foundation for the sophisticated and judicious utilization of ciprofol in clinical landscapes.

Conditions

• Intubation, Intratracheal
• Adverse Effects

Interventions

DRUG

Ciprofol

For induction of anesthesia, an experimental dose of ciprofol was given, and when the patient lost consciousness and the Modified Observer's Alertness/Sedation scale(MOAA/S score) was less than 1, then intravenous sufentanil and rocuronium bromide were administered, and tracheal intubation was performed 3 minutes later

DRUG

Remimazolam

For induction of anesthesia, an experimental dose of remimazolam was given, and when the patient lost consciousness and the Modified Observer's Alertness/Sedation scale(MOAA/S score) was less than 1, then intravenous sufentanil and rocuronium bromide were administered, and tracheal intubation was performed 3 minutes later

Sponsors & Collaborators

• The Second Affiliated Hospital of Hainan Medical University

  lead OTHER

Principal Investigators

• Hu Sun · The Second Affiliated Hospital of Hainan Medical University, Hai Kou, China

• Min Liao · The Second Affiliated Hospital of Hainan Medical University, Hai Kou, China

• Xiaoru Wu · The Second Affiliated Hospital of Hainan Medical University, Hai Kou, China

• Jianing Hu · The Second Affiliated Hospital of Hainan Medical University, Hai Kou, China

• Xingzhou Lin · The Second Affiliated Hospital of Hainan Medical University, Hai Kou, China

• Tangyuanmeng Zhao · West China Hospital

Study Design

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

TRIPLE

Model

PARALLEL

Eligibility

Min Age

18 Years

Max Age

65 Years

Sex

ALL

Healthy Volunteers

Yes

Timeline & Regulatory

Start

2022-07-23

Primary Completion

2023-12-30

Completion

2023-12-30

Countries

• China

Study Locations